Ketamin som hurtig behandling af akut selvmordstanker
Denne undersøgelse vurderede effekten af en enkelt infusion af ketamin til hurtig remission af svær selvmordstanker sammenlignet med Midazolam hos patienter med akutte selvmordstanker. Resultaterne er præsenteret i BMC Res Notes (2025) [doi: 10.1186/s13104-024-07029-7].
Studiet var et dobbeltblindet, randomiseret kontrolleret forsøg, der blev udført i Tehran, Iran, fra januar til juli 2022. Der blev inkluderet 36 indlagte patienter med akutte, svære selvmordstanker. Deltagerne blev tilfældigt tildelt enten en enkelt dosis ketamin (0,5 mg/kg) eller Midazolam (0,02 mg/kg). Evalueringen af suicidale tanker blev udført ved hjælp af Beck Scale for Suicide Ideation (BSSI) og Suicide-Visual Analog Scale (S-VAS) før interventionen samt 12 og 24 timer efter administration.
Primære endepunkter var ændringer i BSSI og S-VAS scores, hvorimod sekundære endepunkter inkluderede vurdering af eventuelle forskelle mellem grupperne. Analyserne viste, at selvom der var en signifikant reduktion i BSSI og S-VAS scores i begge grupper 12 og 24 timer efter behandling, var der ingen statistisk signifikante forskelle mellem ketamin- og Midazolam-grupperne. Det skal bemærkes, at Midazolam-gruppen havde højere BSSI scores og en højere forekomst af borderline personlighedsforstyrrelse ved baseline.
Dette er en AI-genereret oversættelse og opsummering. Læseren bør konsultere den originale kilde for validering og ikke træffe kliniske beslutninger udelukkende på baggrund af dette resumé.
#Psykiatri #Anæstesiologi #Akutmedicin
Læs hele studiet her: [source_link]
Læs hele studiet her: læs her
generer et html link ud fra i
BMC Res Notes. 2025 Feb 12;18(1):65. doi: 10.1186/s13104-024-07029-7.
- PMID: 39940002
- PMCID: PMC11823077
- DOI: 10.1186/s13104-024-07029-7
Abstract
Objective: This study aimed to evaluate the efficacy of a single infusion of ketamine in inducing rapid remission of severe suicidal ideation, compared to Midazolam, in a population with acute suicidal thoughts. In a double-blind randomized controlled trial conducted in Tehran, Iran, from January to July 2022 (IRCT20220118053756N1), 36 inpatients with acute severe suicidal ideation were enrolled. Participants were randomly assigned to receive either a single dose of ketamine (0.5 mg/kg) or Midazolam (0.02 mg/kg). Suicidality was assessed using the Beck Scale for Suicide Ideation (BSSI) and the Suicide-Visual Analog Scale (S-VAS) before the intervention and at 12 and 24 h post-administration.
Results: At baseline, the Midazolam group exhibited significantly higher BSSI scores and a higher rate of borderline personality disorder than the Ketamine group. Mean BSSI and S-VAS scores at 12 and 24 h after the treatment decreased significantly compared to baseline in both groups. Despite these observations, no statistically significant differences were found between the groups in terms of BSSI and S-VAS scores.
Trial registration: The protocol for this RCT was registered at the Iranian Registry of Clinical Trials (IRCT). The trial registration details are as follows: IRCT registration number IRCT20220118053756N1, with the registration date being June 12, 2022 (1401/03/22). It is important to note that this trial was retrospectively registered.
Keywords: Depressive disorder; Ketamine; Midazolam; N-methyl-d-aspartate receptor antagonist; Suicide.
© 2024. The Author(s).
Publication types
- Randomized Controlled Trial
MeSH terms
- Adult
- Double-Blind Method
- Emergency Service, Hospital
- Female
- Humans
- Iran
- Ketamine* / administration & dosage
- Ketamine* / therapeutic use
- Male
- Midazolam* / administration & dosage
- Midazolam* / therapeutic use
- Middle Aged
- Pilot Projects
- Suicidal Ideation*
- Treatment Outcome
- Young Adult
Substances
- Ketamine
- Midazolam